What is the connection between testosterone and prostate health?

Testosterone does not cause prostate cancer, the historical prohibition on TRT in men with prostate cancer was based on the "androgen saturation model" and has been progressively revised since Morgentaler's work established that physiological testosterone restoration does not drive prostate cancer progression in most contexts, but TRT can cause PSA elevation (average 0.3–0.5 ng/mL increase) and may accelerate growth of existing occult prostate cancer, making PSA monitoring mandatory and active prostate cancer a contraindication (Morgentaler & Traish, Eur Urol, 2009).

This is a nuanced area where medical practice has genuinely evolved. The Huggins work from the 1940s established the androgen-prostate cancer connection through the very different context of castration therapy. The claim that TRT causes prostate cancer is not supported by current evidence. The clinically relevant concern is that TRT may accelerate an already-present occult prostate cancer. This is why PSA (and ideally PSA velocity) testing before and during TRT is the clinical standard.

Honesty Scale: Promising (2) for TRT safety in men with no prostate cancer history. Solid (1) for PSA monitoring as a clinical requirement during TRT.

What to do: Have a baseline PSA before starting TRT. If your PSA is above 3.0 ng/mL or rises more than 1.0 ng/mL in any 12-month period on TRT, this warrants a urology consultation before TRT continuation.

For the full picture, read The Testosterone/TRT Deep Dive